Alkermes plc. (ALKS) stock
ALKSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/30208% above fair value
$46.85+1.40 (+3.08%)
Close on Nov 18, 2026Market cap $7.86BP/E 123.3Yield –
Alkermes free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Alkermes's free cash flow for the twelve months ending Jun 30, 2026 was $221.65M, down 53.8% year over year. For fiscal 2025 it was $480.33M, up 18.4% from the year before. The highest annual figure on record is $480.33M in fiscal 2025.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $480.33M | +18.4% |
| FY2024 | Dec 31, 2024 | $405.64M | +14.8% |
| FY2023 | Dec 31, 2023 | $353.31M | – |
| FY2022 | Dec 31, 2022 | -$17.21M | -123.4% |
| FY2021 | Dec 31, 2021 | $73.70M | +81.4% |
| FY2020 | Dec 31, 2020 | $40.62M | – |
| FY2019 | Dec 31, 2019 | -$18.87M | -163.2% |
| FY2018 | Dec 31, 2018 | $29.85M | – |
| FY2017 | Dec 31, 2017 | -$32.11M | – |
| FY2016 | Dec 31, 2016 | -$107.46M | – |
| FY2015 | Dec 31, 2015 | -$93.24M | -189.4% |
| FY2013 | Mar 31, 2013 | $104.33M | – |
| FY2012 | Mar 31, 2012 | -$19.47M | – |
| FY2011 | Mar 31, 2011 | -$15.31M | – |
| FY2010 | Mar 31, 2010 | -$28.03M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $137.04M | -0.1% |
| Q1 FY2026 | Mar 31, 2026 | -$169.83M | -291.5% |
| Q4 FY2025 | Dec 31, 2025 | $170.09M | -5.8% |
| Q3 FY2025 | Sep 30, 2025 | $84.36M | +15.0% |
| Q2 FY2025 | Jun 30, 2025 | $137.19M | -1.2% |
| Q1 FY2025 | Mar 31, 2025 | $88.70M | +594.8% |
| Q4 FY2024 | Dec 31, 2024 | $180.62M | +100.2% |
| Q3 FY2024 | Sep 30, 2024 | $73.33M | -14.0% |
| Q2 FY2024 | Jun 30, 2024 | $138.92M | -32.6% |
| Q1 FY2024 | Mar 31, 2024 | $12.77M | – |
| Q4 FY2023 | Dec 31, 2023 | $90.21M | – |
| Q3 FY2023 | Sep 30, 2023 | $85.26M | – |
| Q2 FY2023 | Jun 30, 2023 | $206.01M | – |
| Q1 FY2023 | Mar 31, 2023 | -$28.16M | -302.8% |
| Q4 FY2022 | Dec 31, 2022 | -$8.98M | -140.2% |
| Q3 FY2022 | Sep 30, 2022 | -$9.85M | -112.6% |
| Q2 FY2022 | Jun 30, 2022 | -$12.27M | -146.3% |
| Q1 FY2022 | Mar 31, 2022 | $13.89M | – |
| Q4 FY2021 | Dec 31, 2021 | $22.36M | -63.9% |
| Q3 FY2021 | Sep 30, 2021 | $77.96M | +44.9% |
| Q2 FY2021 | Jun 30, 2021 | $26.50M | – |
| Q1 FY2021 | Mar 31, 2021 | -$53.13M | – |
| Q4 FY2020 | Dec 31, 2020 | $61.90M | +512.9% |
| Q3 FY2020 | Sep 30, 2020 | $53.80M | +366.1% |
| Q2 FY2020 | Jun 30, 2020 | -$15.01M | – |
| Q1 FY2020 | Mar 31, 2020 | -$60.07M | – |
| Q4 FY2019 | Dec 31, 2019 | $10.10M | -76.5% |
| Q3 FY2019 | Sep 30, 2019 | $11.54M | -32.3% |
| Q2 FY2019 | Jun 30, 2019 | -$39.08M | -357.3% |
| Q1 FY2019 | Mar 31, 2019 | -$1.43M | – |
| Q4 FY2018 | Dec 31, 2018 | $42.92M | +137.3% |
| Q3 FY2018 | Sep 30, 2018 | $17.06M | +156.4% |
| Q2 FY2018 | Jun 30, 2018 | $15.19M | – |
| Q1 FY2018 | Mar 31, 2018 | -$45.32M | – |
| Q4 FY2017 | Dec 31, 2017 | $18.09M | – |
| Q3 FY2017 | Sep 30, 2017 | $6.65M | +106.3% |
| Q2 FY2017 | Jun 30, 2017 | -$33.73M | – |
| Q1 FY2017 | Mar 31, 2017 | -$23.13M | – |
| Q4 FY2016 | Dec 31, 2016 | -$2.31M | – |
| Q3 FY2016 | Sep 30, 2016 | $3.23M | – |
See a number that looks wrong?